USPTO Examiner RASNIC HUNTER J - Art Unit 3626

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17104045MULTI-STAGE TREATMENT RECOMMENDATIONSNovember 2020May 2024Abandon4140YesNo
17094991Document Management System and MethodNovember 2020March 2023Abandon2810NoNo
17007620Web-Based Personalized Health Management SystemAugust 2020July 2023Abandon3520NoNo
16937577Methods of Cross Correlation of Biofield Scans to Enome Database, Genome Database, Blood Test, and Phenotype DataJuly 2020April 2023Abandon3210NoNo
16891330Intelligent Robot-Based Rehabilitation Training Method For Patient With DementiaJune 2020February 2023Abandon3210NoNo
16695642Systems and Methods for Processing Medical Images For In-Progress StudiesNovember 2019December 2023Allow4840YesNo
16689314AUTOMATED ELECTRONIC MEDICAL RECORD (EMR) ANALYSIS VIA POINT OF CARE COMPUTING SYSTEMSNovember 2019August 2024Abandon5760YesNo
16689773Patient-Centric Eco-System with Automated Workflow and Facility Manager for Improved Delivery of Medical ServicesNovember 2019July 2023Abandon4420NoNo
16673726PATIENT RISK SCORING AND EVALUATION SYSTEMS AND METHODSNovember 2019November 2021Abandon2410NoNo
16669357METHODS AND SYSTEMS FOR PATIENT CONTROL OF AN ELECTRONIC PRESCRIPTIONOctober 2019August 2023Allow4630YesNo
16663223STRESS MANAGEMENT IN CLINICAL SETTINGSOctober 2019August 2022Abandon3430YesNo
16659885EMOTION DETECTION FROM CONTEXTUAL SIGNALS FOR SURFACING WELLNESS INSIGHTSOctober 2019March 2022Abandon2920YesNo
16583357LONGITUDINAL DATA DE-IDENTIFICATIONSeptember 2019August 2024Abandon5960YesNo
16508653METHODS AND SYSTEMS FOR DATA ANALYTICS OF METRICS FOR OUTCOMES AND PAY-FOR-PERFORMANCE MODELSJuly 2019February 2022Abandon3120YesNo
16504565IDENTIFICATION OF EPIDEMIOLOGY TRANSMISSION HOT SPOTS IN A MEDICAL FACILITYJuly 2019September 2023Allow5040YesNo
16462291SYSTEM AND METHODS FOR CALCULATING, DISPLAYING, MODIFYING, AND USING IMPROVED PERSONALIZED NUTRITIONAL HEALTH SCORE TO ASSESS AND PLAN OPTIMAL DIETSMay 2019July 2024Abandon6060YesNo
16380248RECORDING DEVICE, ORDER ISSUING DEVICE AND ANALYSIS PROCESSING SYSTEMApril 2019October 2023Abandon5460YesNo
16380019ARTIFICIAL INTELLIGENCE AIDED BUG BITE AND TRANSMITTED DISEASE IDENTIFICATIONApril 2019December 2022Abandon4440YesNo
16379640CUSTOMIZED HEALTHCARE MANAGEMENT OF A LIVING SUBJECTApril 2019May 2021Abandon2510NoNo
16379776DATABASE MANAGEMENT SYSTEM FOR DYNAMIC POPULATION STRATIFICATION BASED ON DATA STRUCTURES HAVING FIELDS STRUCTUING DATA RELATED TO CHANGING ENTITY ATTRIBUTESApril 2019June 2023Abandon5040YesNo
16337742DEMENTIA CARE BURDEN LEVEL DETERMINATION DEVICE, METHOD, AND RECORDING MEDIUM, AND DEMENTIA TREATMENT THERAPEUTIC EFFECT DETERMINATION DEVICE, METHOD, AND RECORDING MEDIUMMarch 2019September 2023Abandon5450YesNo
16289654SYSTEM AND METHOD FOR ESTIMATING PATHOGEN TRANSFER FROM MOBILE INTERACTION IN CLINICAL ENVIRONMENTS AND A WARNING SYSTEM AND METHOD FOR REDUCING CROSS-CONTAMINATION RISKSFebruary 2019October 2021Allow3220YesNo
16288078System and Method for the Specialized Delivery of Telemedicine ServicesFebruary 2019January 2022Abandon3520NoNo
16285757MEDICAL RECOMMENDATION PLATFORMFebruary 2019August 2021Abandon2920NoNo
16301451COMPUTER SYSTEM FOR RAPID VISUAL TRACKING OF THE STATUS OF ONE OR MORE HOSPITAL DEPARTMENTSNovember 2018March 2021Abandon2810NoNo
16182278COMMUNICATION OF DATA WHERE A SURGICAL NETWORK IS USING CONTEXT OF THE DATA AND REQUIREMENTS OF A RECEIVING SYSTEM / USER TO INFLUENCE INCLUSION OR LINKAGE OF DATA AND METADATA TO ESTABLISH CONTINUITYNovember 2018July 2023Abandon5650YesNo
16178178METHOD AND SYSTEM FOR LOCALIZING A HANDHELD ANALYTICAL DEVICENovember 2018October 2023Abandon5950YesNo
16098021ENHANCED DECISION SUPPORT FOR SYSTEMS, METHODS, AND MEDIA FOR LABORATORY BENEFIT SERVICESOctober 2018March 2021Abandon2920YesNo
16141753HEALTH EVENT HIGHLIGHTERSeptember 2018June 2023Allow5660YesNo
16140414PROSPECTIVE MEDICATION FILLINGS MANAGEMENTSeptember 2018October 2023Allow6060YesNo
16110233System and Method for Populating and Processing Prescription ScriptsAugust 2018January 2021Abandon2910NoNo
16039129MINIMALLY INVASIVE PROCEDURE ANALYSIS AND REVIEW SYSTEM AND METHODJuly 2018March 2024Abandon6021YesNo
16020085Patient Support Systems And Methods For Assisting Caregivers With Patient CareJune 2018July 2023Allow6060YesNo
16066597A PATIENT PROCEDURE SCHEDULE THROUGHPUT OPTIMISER SUPERVISED MACHINE LEARNING SYSTEMJune 2018December 2020Abandon2910NoNo
16019581CLINICAL TRIAL SEARCHING AND MATCHINGJune 2018May 2021Abandon3420YesNo
16066348DEVICE, SYSTEM, AND METHOD FOR OPTIMIZING A PATIENT FLOWJune 2018February 2021Abandon3210NoNo
16019788MANAGEMENT OF COMFORT STATES OF AN ELECTRONIC DEVICE USERJune 2018July 2022Abandon4930YesNo
16066488IMAGE DISPLAY DEVICE AND IMAGE DISPLAY METHODJune 2018June 2021Abandon3620NoNo
16066368METHOD AND SYSTEM TO IDENTIFY DOMINANT PATTERNS OF HEALTHCARE UTILIZATION AND COST-BENEFIT ANALYSIS OF INTERVENTIONSJune 2018March 2021Abandon3320NoNo
16019865AUTOMATED HEALTHCARE SYSTEMJune 2018January 2024Abandon6040YesYes
16019497NORMALIZATION OF MEDICAL TERMSJune 2018May 2023Allow5950YesNo
15773258Patient Outcome Tracking PlatformMay 2018May 2024Abandon6080YesNo
15967217ROUTE SCHEDULING OF MULTI-CLASS TRANSPORT VEHICLESApril 2018December 2021Abandon4330YesNo
15966749Systems and Methods for Analyzing Health Care Data to Improve Billing and Decision ProcessesApril 2018October 2020Abandon3010NoNo
15772318Methods of Cross Correlation of Biofield Scans to Enome Database, Genome Database, Blood Test, and Phenotype DataApril 2018October 2020Abandon3010NoNo
15770303MIND-ALTERING SUBSTANCE TESTING SYSTEMApril 2018May 2024Abandon6090YesNo
15955456SYSTEM AND METHOD FOR PATIENT TRACKING DURING MASS CASUALTY EVENTSApril 2018July 2023Allow6080YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RASNIC, HUNTER J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
15.4%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
8.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner RASNIC, HUNTER J - Prosecution Strategy Guide

Executive Summary

Examiner RASNIC, HUNTER J works in Art Unit 3626 and has examined 47 patent applications in our dataset. With an allowance rate of 19.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner RASNIC, HUNTER J's allowance rate of 19.1% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by RASNIC, HUNTER J receive 3.36 office actions before reaching final disposition. This places the examiner in the 90% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by RASNIC, HUNTER J is 43 months. This places the examiner in the 17% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +30.0% benefit to allowance rate for applications examined by RASNIC, HUNTER J. This interview benefit is in the 77% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 6.2% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 6.5% of cases where such amendments are filed. This entry rate is in the 8% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 1% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 92% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 33% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 38% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.